Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Immunovant, Inc. - Common Stock (NQ:IMVT)

14.56 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, May 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Immunovant, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Stock Market Rally Is In Merry Mood Heading Into Christmas Weekend: Weekly Review
Despite a Wednesday tumble, the major indexes are right at 2023 highs. 
Via Investor's Business Daily
Why CarMax Shares Are Trading Higher By Around 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of CarMax, Inc. (NYSE: KMX) moved higher during Thursday’s session following better-than-expected quarterly earnings. 
Via Benzinga
Argenx Dives On Autoimmune Therapy Failure
A treatment for a skin-blistering condition failed to beat a placebo. 
Via Investor's Business Daily
Analyst Ratings for Immunovant
Via Benzinga
Where Immunovant Stands With Analysts
Via Benzinga
Immunovant Scores Much-Needed Win Following Argenx-Led Sell-off
Immunovant reversed its fortunes Thursday following an Argenx-tied selloff Wednesday. 
Via Investor's Business Daily
Autoimmune Disease Player Immunovant's Investigational Drug For Immune System Disorder Shows Response Rates Of Over 50%
Immunovant Inc (NASDAQ: IMVT), on Thursday, released the results from the initial cohort of patients in an ongoing 24-week Phase 2 trial of batoclimab in  
Via Benzinga
Amazon.com To Rally Over 38%? Here Are 10 Top Analyst Forecasts For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
Micron Posts Upbeat Sales, Joins Calliditas Therapeutics And Other Big Stocks Moving Higher In Thursday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow Jones futures gaining more than 150 points on Thursday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease
From Roivant Sciences
Via GlobeNewswire
Recap: Immunovant Q2 Earnings
Via Benzinga
The Latest Analyst Ratings for Immunovant
Via Benzinga
Why Steelcase Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Steelcase Inc. (NYSE: SCS) shares moved higher during Wednesday's session following quarterly results. 
Via Benzinga
FedEx Posts Downbeat Earnings, Joins Steelcase, argenx And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures were lower this morning, with the Dow Jones futures falling around 30 points on Wednesday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Dow Jones Hits 2023 High, Nasdaq Slips; Tesla Cybertruck, Salesforce In Focus: Weekly Review
Software earnings were strong, while the Fed is shifting toward rate cuts. 
Via Investor's Business Daily
Topics Economy Stocks
Exposures Interest Rates US Equities
Roivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential
From Roivant Sciences
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For October 13, 2023
Via Benzinga
Lamb Weston, SP Plus And Other Big Stocks Moving Higher On Thursday
U.S. stocks traded lower, with the Nasdaq Composite falling around 100 points on Thursday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
Exposures US Equities
Stock Market Rally Attempt Underway; Micron, Nike, Amazon, Meta In Focus: Weekly Review
But it's not a confirmed uptrend yet. Nike, Amazon and Meta were in focus. 
Via Investor's Business Daily
What's Going On Pfizer's Subsidiary Biohaven Stock?
Pfizer Inc's (NYSE: PFE) subsidiary Biohaven Ltd (NYSE: BHVN) released an  
Via Benzinga
Why Sharps Technology Shares Are Trading Lower By Around 32%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers 
Via Benzinga
Biohaven, Yet Another Argenx Rival In Autoimmune Drugs, Just Rocketed 29%
The companies hope by lowering immunoglobulin G, an antibody, that they can treat myriad autoimmune diseases. 
Via Investor's Business Daily
Why Immunovant Stock Is Bolting Higher Today
The company may have best-in-class autoimmune disease therapy under its roof. 
Via The Motley Fool
Immunovant Parlays Its Shot At Rivaling Argenx Into A $300 Million Offering
Both companies are working on drugs that lower an antibody tied to numerous autoimmune conditions. 
Via Investor's Business Daily
MillerKnoll, Hayward Holdings, Ginkgo Bioworks And Other Big Stocks Moving Higher On Wednesday
U.S. stocks traded mostly higher, with the Nasdaq Composite gaining around 40 points on Wednesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
Exposures US Equities
Roivant Stock Price Outlook: Strong Pipeline Is A Catalyst
Roivant Sciences has 12 drugs in its pipeline. The company’s Immunovant subsidiary reported strong results for its drug. Roivant is in talks with Roche to sell its Chron’s disease for $7 billion. 
Via Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For September 27, 2023
Via Benzinga
Why Shares of Immunovant Are Soaring on Tuesday
Immunovant sees strong potential for an autoimmune disorder therapy. 
Via The Motley Fool
Nasdaq Down 1.5%; Immunovant Shares Spike Higher
U.S. stocks traded lower toward the end of trading, with the Dow Jones falling more than 400 points on Tuesday. The Dow traded down 1.19% to 33,601.60 while the NASDAQ fell 1.48% to 13,074.97. The S&P... 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.